Brief: SK Bioscience To Invest 284 Billion Won In Research & Process Development Center In S.Korea
08/02/2023 07:14
Feb 8 (Reuters) - SK Bioscience Co Ltd 302440.KS :
* TO INVEST 284 BILLION WON IN RESEARCH & PROCESS
DEVELOPMENT
CENTER IN S.KOREA TO EXPAND VACCINE BUSINESS
Further company coverage: 302440.KS
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine